[{"id":"310e9d9a-b69c-4442-97f5-d4d4ad2729a2","acronym":"NCI-2018-00918","url":"https://clinicaltrials.gov/study/NCT03449108","created_at":"2022-07-22T15:57:20.497Z","updated_at":"2024-07-02T16:35:02.803Z","phase":"Phase 2","brief_title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","source_id_and_acronym":"NCT03449108 - NCI-2018-00918","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • CD8 • CD28 • CD27","pipe":" | ","alterations":" CD8 expression • CD28 expression","tags":["HER-2 • CD8 • CD28 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/27/2018","start_date":" 04/27/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-17"},{"id":"21770a2b-94fa-4c90-9baa-415238e0293a","acronym":"IOV-LUN-202","url":"https://clinicaltrials.gov/study/NCT04614103","created_at":"2021-01-19T20:33:10.456Z","updated_at":"2024-07-02T16:35:04.786Z","phase":"Phase 2","brief_title":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT04614103 - IOV-LUN-202","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • LN-145"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 05/07/2021","start_date":" 05/07/2021","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-05-09"},{"id":"edb2b274-13c3-4f98-902d-b4c8c73c839a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04111510","created_at":"2021-01-18T20:06:11.021Z","updated_at":"2024-07-02T16:35:17.784Z","phase":"Phase 2","brief_title":"Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT04111510","lead_sponsor":"Yale University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LN-145"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 12/23/2019","start_date":" 12/23/2019","primary_txt":" Primary completion: 01/30/2023","primary_completion_date":" 01/30/2023","study_txt":" Completion: 05/11/2023","study_completion_date":" 05/11/2023","last_update_posted":"2024-02-23"}]